Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib in Chronic Myelogenous Leukemia (CML)
NCT00023881Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2001
- Primary completion
- Mar 2005
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in chronic myelogenous leukemia (CML), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Objective Response Rate, Duration of Response and 2 more. Started Jul 2001; status: terminated.
02
Drugs
bortezomib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NCT00023881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00023881.